JP2004522794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004522794A5 JP2004522794A5 JP2002569851A JP2002569851A JP2004522794A5 JP 2004522794 A5 JP2004522794 A5 JP 2004522794A5 JP 2002569851 A JP2002569851 A JP 2002569851A JP 2002569851 A JP2002569851 A JP 2002569851A JP 2004522794 A5 JP2004522794 A5 JP 2004522794A5
- Authority
- JP
- Japan
- Prior art keywords
- deoxy
- chloro
- compound
- methyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 125000004434 sulfur atom Chemical group 0.000 claims 15
- 239000004480 active ingredient Substances 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000006277 halobenzyl group Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 150000003931 anilides Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- RPEOMBNGFDGGGF-AZRMKWAISA-N (2r,3r,4r,5r)-5-(6-amino-2-fluoropurin-9-yl)-2-(1-hydroxyethyl)-4-sulfanyloxolan-3-ol Chemical compound S[C@@H]1[C@H](O)[C@@H](C(O)C)O[C@H]1N1C2=NC(F)=NC(N)=C2N=C1 RPEOMBNGFDGGGF-AZRMKWAISA-N 0.000 claims 2
- NISIMUBLAKINBA-WOUKDFQISA-N (2r,3r,4s,5r)-2-(6-amino-2-chloropurin-9-yl)-5-(cyclopropyloxymethyl)oxolane-3,4-diol Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=C(Cl)N=C(C=2N=C1)N)OC1CC1 NISIMUBLAKINBA-WOUKDFQISA-N 0.000 claims 2
- DIRSXCWAEPAXAQ-IOSLPCCCSA-N (2r,3r,4s,5r)-2-(6-amino-2-chloropurin-9-yl)-5-(ethoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COCC)O[C@H]1N1C2=NC(Cl)=NC(N)=C2N=C1 DIRSXCWAEPAXAQ-IOSLPCCCSA-N 0.000 claims 2
- ONEJIJDFNYJRAY-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-chloropurin-9-yl)-5-(methoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COC)O[C@H]1N1C2=NC(Cl)=NC(N)=C2N=C1 ONEJIJDFNYJRAY-KQYNXXCUSA-N 0.000 claims 2
- XJHWWEZNNZWQSZ-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(cyclopropyloxymethyl)oxolane-3,4-diol Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C2=NC(Cl)=NC(NC3CCCC3)=C2N=C1)O)O)OC1CC1 XJHWWEZNNZWQSZ-LSCFUAHRSA-N 0.000 claims 2
- AWTMTQOYFLGHJN-XNIJJKJLSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(ethoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COCC)O[C@H]1N1C2=NC(Cl)=NC(NC3CCCC3)=C2N=C1 AWTMTQOYFLGHJN-XNIJJKJLSA-N 0.000 claims 2
- BEAMUZQXJYLFAG-SDBHATRESA-N (2r,3r,4s,5r)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(methoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COC)O[C@H]1N1C2=NC(Cl)=NC(NC3CCCC3)=C2N=C1 BEAMUZQXJYLFAG-SDBHATRESA-N 0.000 claims 2
- CPZMUYPOIXKZIA-NVQRDWNXSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-5-(cyclopropyloxymethyl)oxolane-3,4-diol Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1)O)O)OC1CC1 CPZMUYPOIXKZIA-NVQRDWNXSA-N 0.000 claims 2
- IJKYHPSTWVHGBB-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-5-(ethoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COCC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IJKYHPSTWVHGBB-SCFUHWHPSA-N 0.000 claims 2
- JVYDOJWIEYGRHJ-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-5-(methoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 JVYDOJWIEYGRHJ-LSCFUAHRSA-N 0.000 claims 2
- BCRRZUTYWZJGKE-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-(cyclopentylamino)purin-9-yl]-5-(ethoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COCC)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 BCRRZUTYWZJGKE-LSCFUAHRSA-N 0.000 claims 2
- WBBKLNODPBVNAO-XNIJJKJLSA-N (2r,3r,4s,5r)-2-[6-(cyclopentylamino)purin-9-yl]-5-(methoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COC)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 WBBKLNODPBVNAO-XNIJJKJLSA-N 0.000 claims 2
- QFZYZNWVNVQKTI-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[(3-iodophenyl)methylamino]purin-9-yl]-5-(methoxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 QFZYZNWVNVQKTI-SCFUHWHPSA-N 0.000 claims 2
- UHUUFZRMGIEYPU-QYVSTXNMSA-N (2r,3r,4s,5s)-2-(6-amino-2-chloropurin-9-yl)-5-(butylsulfanylmethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCCCC)O[C@H]1N1C2=NC(Cl)=NC(N)=C2N=C1 UHUUFZRMGIEYPU-QYVSTXNMSA-N 0.000 claims 2
- LETCMYXPSWWGKO-NVQRDWNXSA-N (2r,3s,4r,5r)-2-(ethoxymethyl)-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](COCC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 LETCMYXPSWWGKO-NVQRDWNXSA-N 0.000 claims 2
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 claims 2
- FRMLKDCRCIWDMU-VNOIWZSWSA-N C1(CCCC1)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](COC4CC4)O3)C2=NC=N1)N Chemical compound C1(CCCC1)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](COC4CC4)O3)C2=NC=N1)N FRMLKDCRCIWDMU-VNOIWZSWSA-N 0.000 claims 2
- IWDCHYDENFRGTM-BGIGGGFGSA-N CCCCCCC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CC(C)C)O)S)N Chemical compound CCCCCCC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CC(C)C)O)S)N IWDCHYDENFRGTM-BGIGGGFGSA-N 0.000 claims 2
- UJBKDSPTUBDQQB-IWCJZZDYSA-N CCCCCCC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CC)O)S)N Chemical compound CCCCCCC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CC)O)S)N UJBKDSPTUBDQQB-IWCJZZDYSA-N 0.000 claims 2
- SXEJLJUMSQKGMI-XKLVTHTNSA-N CCCCCCC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CCC)O)S)N Chemical compound CCCCCCC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CCC)O)S)N SXEJLJUMSQKGMI-XKLVTHTNSA-N 0.000 claims 2
- VYEHWRWELDGJKE-BGIGGGFGSA-N CCCCCCC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CCCC)O)S)N Chemical compound CCCCCCC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CCCC)O)S)N VYEHWRWELDGJKE-BGIGGGFGSA-N 0.000 claims 2
- XYGGNUPCLTYUPQ-KQYNXXCUSA-N ClC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CC)O3)C2N1)N Chemical compound ClC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CC)O3)C2N1)N XYGGNUPCLTYUPQ-KQYNXXCUSA-N 0.000 claims 2
- XHUVBQWYNADUTO-IOSLPCCCSA-N ClC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CCC)O3)C2N1)N Chemical compound ClC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CCC)O3)C2N1)N XHUVBQWYNADUTO-IOSLPCCCSA-N 0.000 claims 2
- OOOYQDXRLCJODT-BYPQGEBLSA-N IC=1C=C(CC2(C3=NCN([C@H]4[C@H](O)[C@H](O)[C@@H](COC5CC5)O4)C3=NC=N2)N)C=CC=1 Chemical compound IC=1C=C(CC2(C3=NCN([C@H]4[C@H](O)[C@H](O)[C@@H](COC5CC5)O4)C3=NC=N2)N)C=CC=1 OOOYQDXRLCJODT-BYPQGEBLSA-N 0.000 claims 2
- BEJOUTLNHRKQJN-WOUKDFQISA-N IC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CC(C)C)O3)C2N1)N Chemical compound IC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CC(C)C)O3)C2N1)N BEJOUTLNHRKQJN-WOUKDFQISA-N 0.000 claims 2
- DPNYFSJWJYNHCS-KQYNXXCUSA-N IC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CC)O3)C2N1)N Chemical compound IC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CC)O3)C2N1)N DPNYFSJWJYNHCS-KQYNXXCUSA-N 0.000 claims 2
- HMZXGGNPWPRMTB-IOSLPCCCSA-N IC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CCC)O3)C2N1)N Chemical compound IC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CCC)O3)C2N1)N HMZXGGNPWPRMTB-IOSLPCCCSA-N 0.000 claims 2
- MFAMUKGBUIBIFP-WOUKDFQISA-N IC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CCCC)O3)C2N1)N Chemical compound IC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CCCC)O3)C2N1)N MFAMUKGBUIBIFP-WOUKDFQISA-N 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- -1 2-fluoro-5'-ethylthioadenosine Chemical compound 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- AVIMYKINTNKGAW-IOSLPCCCSA-N FC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CCC)O3)C2N1)N Chemical compound FC=1N=C(C=2N=CN([C@H]3[C@H](S)[C@H](O)[C@@H](CCC)O3)C2N1)N AVIMYKINTNKGAW-IOSLPCCCSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0105337A GB2372742A (en) | 2001-03-03 | 2001-03-03 | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
| PCT/IL2002/000160 WO2002070532A2 (en) | 2001-03-03 | 2002-03-03 | C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008310049A Division JP2009167170A (ja) | 2001-03-03 | 2008-12-04 | Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004522794A JP2004522794A (ja) | 2004-07-29 |
| JP2004522794A5 true JP2004522794A5 (https=) | 2005-06-30 |
| JP4359676B2 JP4359676B2 (ja) | 2009-11-04 |
Family
ID=9909952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569851A Expired - Fee Related JP4359676B2 (ja) | 2001-03-03 | 2002-03-03 | Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用 |
| JP2008310049A Pending JP2009167170A (ja) | 2001-03-03 | 2008-12-04 | Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008310049A Pending JP2009167170A (ja) | 2001-03-03 | 2008-12-04 | Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7084127B2 (https=) |
| EP (1) | EP1368365A2 (https=) |
| JP (2) | JP4359676B2 (https=) |
| KR (1) | KR100585894B1 (https=) |
| CN (1) | CN1259332C (https=) |
| AU (1) | AU2002234851A1 (https=) |
| CA (1) | CA2439879C (https=) |
| GB (1) | GB2372742A (https=) |
| WO (1) | WO2002070532A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005527502A (ja) * | 2002-02-19 | 2005-09-15 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ１アデノシン受容体の部分的および全アゴニスト |
| JP2005132767A (ja) * | 2003-10-30 | 2005-05-26 | Sumitomo Chemical Co Ltd | プリン化合物の製造方法 |
| CA2550299C (en) * | 2003-12-22 | 2010-03-30 | Christopher R. Roberts | Process for fluorocytidine derivatives |
| US20050277615A1 (en) * | 2004-05-17 | 2005-12-15 | Can-Fite Biopharma Ltd. | Pharmaceutical compositions having anti-inflammatory activity |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| US20080070860A1 (en) * | 2005-02-04 | 2008-03-20 | Uti Limited Partnership | Adenosine Analogs Useful as Anti-Bacterial and Anti Protozoan Agents |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| AU2009231978C1 (en) * | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| EP2331542B1 (en) * | 2008-08-01 | 2016-07-27 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | A3 adenosine receptor antagonists and partial agonists |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| WO2011010306A1 (en) | 2009-07-21 | 2011-01-27 | Ramot At Tel-Aviv University Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| SG182285A1 (en) | 2010-01-11 | 2012-08-30 | Inotek Pharmaceuticals Corp | Combination, kit and method of reducing intraocular pressure |
| EA201290958A1 (ru) | 2010-03-26 | 2013-04-30 | Инотек Фармасьютикалз Корпорейшн | Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств |
| BR112014018413A8 (pt) | 2012-01-26 | 2017-07-11 | Inotek Pharmaceuticals Corp | Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo |
| WO2014068589A2 (en) * | 2012-10-29 | 2014-05-08 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel process for the preparation of (1-{9-[(4s, 2r, 3r, 5r)-3, 4-dihydroxy-5-(hydroxymethyl) oxolan-2-yl)-6-aminopurin-2-yl} pyrazole-4-yl)-n-methylcarboxamide |
| CA2903114A1 (en) | 2013-03-15 | 2014-09-25 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
| EP3448015B1 (en) * | 2016-04-22 | 2021-11-24 | Kowa Company, Ltd. | Image capturing device provided with multiplexer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4357324A (en) | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
| US5189027A (en) * | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
| US5278150A (en) * | 1992-04-24 | 1994-01-11 | Whitby Research, Inc. | 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| WO1997033591A1 (en) * | 1996-03-13 | 1997-09-18 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| GB9610031D0 (en) | 1996-05-14 | 1996-07-17 | Glaxo Group Ltd | Chemical compounds |
| US5998423A (en) * | 1996-10-08 | 1999-12-07 | Therasys, Inc. | Methods for modulating melanin production |
| GB9723566D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| DE69932173T2 (de) * | 1998-10-16 | 2007-06-06 | Pfizer Inc. | Adeninderivate |
| WO2000072799A2 (en) * | 1999-05-27 | 2000-12-07 | The University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| WO2001040799A2 (en) * | 1999-12-03 | 2001-06-07 | Cv Therapeutics, Inc. | Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias |
-
2001
- 2001-03-03 GB GB0105337A patent/GB2372742A/en not_active Withdrawn
-
2002
- 2002-03-03 US US10/469,735 patent/US7084127B2/en not_active Expired - Fee Related
- 2002-03-03 JP JP2002569851A patent/JP4359676B2/ja not_active Expired - Fee Related
- 2002-03-03 AU AU2002234851A patent/AU2002234851A1/en not_active Abandoned
- 2002-03-03 EP EP02701520A patent/EP1368365A2/en not_active Withdrawn
- 2002-03-03 WO PCT/IL2002/000160 patent/WO2002070532A2/en not_active Ceased
- 2002-03-03 CA CA002439879A patent/CA2439879C/en not_active Expired - Fee Related
- 2002-03-03 KR KR1020037011508A patent/KR100585894B1/ko not_active Expired - Fee Related
- 2002-03-03 CN CNB028072014A patent/CN1259332C/zh not_active Expired - Fee Related
-
2003
- 2003-09-03 US US10/653,464 patent/US7189706B2/en not_active Expired - Fee Related
-
2008
- 2008-12-04 JP JP2008310049A patent/JP2009167170A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004522794A5 (https=) | ||
| JP2004531523A5 (https=) | ||
| JP5230052B2 (ja) | フラビウイルスおよびペスチウイルス治療のための方法および組成物 | |
| JP2015512860A5 (https=) | ||
| CN111971284A (zh) | 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式 | |
| JP2008512457A5 (https=) | ||
| JP2007519649A5 (https=) | ||
| JP2010528987A5 (https=) | ||
| JP2023518973A5 (https=) | ||
| TW200526237A (en) | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | |
| JP2010515760A5 (https=) | ||
| TR200103607T2 (tr) | Pürin Türevleri | |
| JP2005537268A5 (https=) | ||
| JP2004534850A5 (https=) | ||
| JP2009500423A5 (https=) | ||
| CN1950376A (zh) | 莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途 | |
| RU2008145714A (ru) | Пуриновые производные в качестве активатора аденозинового рецептора | |
| JP2009541349A (ja) | プロドラッグである５−アミノ−３−（３’−デオキシ−β−Ｄ−リボフラノシル）−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン | |
| RU2002103883A (ru) | Перорально активные андрогены | |
| JP2007332144A (ja) | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 | |
| JP2005526024A5 (https=) | ||
| JP2023549494A5 (https=) | ||
| JP6990934B2 (ja) | 異所性脂肪蓄積治療用ａ３アデノシン受容体リガンド | |
| RU2007118729A (ru) | Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а | |
| JPH10245391A5 (https=) |